纪伟, 刘相良, 芦晋, 郑开文, 杨海梅, 马责竣, 崔久嵬, 李薇. 相位角在小细胞肺癌患者预后预测中的应用[J]. 中国肿瘤临床, 2020, 47(21): 1115-1118. DOI: 10.3969/j.issn.1000-8179.2020.21.304
引用本文: 纪伟, 刘相良, 芦晋, 郑开文, 杨海梅, 马责竣, 崔久嵬, 李薇. 相位角在小细胞肺癌患者预后预测中的应用[J]. 中国肿瘤临床, 2020, 47(21): 1115-1118. DOI: 10.3969/j.issn.1000-8179.2020.21.304
shu
Ji Wei, Liu Xiangliang, Lu Jin, Zheng Kaiwen, Yang Haimei, Ma Zejun, Cui Jiuwei, Li Wei. Role of whole-body phase angle in prognosis of small cell lung cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(21): 1115-1118. DOI: 10.3969/j.issn.1000-8179.2020.21.304
Citation: Ji Wei, Liu Xiangliang, Lu Jin, Zheng Kaiwen, Yang Haimei, Ma Zejun, Cui Jiuwei, Li Wei. Role of whole-body phase angle in prognosis of small cell lung cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 47(21): 1115-1118. DOI: 10.3969/j.issn.1000-8179.2020.21.304
shu

相位角在小细胞肺癌患者预后预测中的应用

Role of whole-body phase angle in prognosis of small cell lung cancer

    摘要
  • 摘要:
      目的  早期研究表明相位角（phase angle，PhA）与肿瘤患者预后有关，本研究分析PhA在小细胞肺癌（small cell lung cancer，SCLC）患者预后预测中的作用。
      方法  筛选2015年1月至2017年8月间吉林大学第一医院初诊SCLC患者148例，记录患者初诊时年龄、体质指数（body mass index，BMI）、肿瘤分期和无进展生存期（progression-free survival，PFS），采用Inbody（Biospace Co®）测量患者初诊时PhA。按照性别分层后，根据PhA第2三分位界值将其分为低值组和高值组。应用Kaplan-Meier生存分析及Log-rank检验比较生存关系，采用Cox比例风险模型进行多因素分析。
      结果  男性患者PhA为（5.56±0.71）°，女性患者PhA为（4.69±0.91）°，差异具有统计学意义（P < 0.001）。多因素Cox回归分析结果显示：PhA是小细胞肺癌患者PFS的独立危险因素（HR=0.646，95% CI：0.486~0.860，P=0.003）。低PhA组患者中位PFS为7.77个月，高PhA组患者中位PFS为10.5个月，生存分析显示2组患者PFS差异具有统计学意义（P < 0.05）。
      结论  男性和女性SCLC患者PhA存在差异，基线PhA水平可以预测小细胞肺癌患者的预后。需要大样本研究探索不同性别和疾病状态下东亚人种应用PhA评价细胞健康和功能的有效界值，以更好的指导治疗和预后预测。

     

    Abstract:
      Objective  Early investigations suggested that whole-body phase angle (PhA) was associated with prognostic prediction in patients with cancer. This study aimed to investigate the role of PhA in prognostic prediction in patients with small cell lung cancer (SCLC).
      Methods  We retrospectively analyzed 148 newly diagnosed cases of SCLC in The First Affiliated Hospital of Jilin University from January 2015 to July 2017. Progression-free survival (PFS) and prognostic factors, including age, body mass index (BMI), and stage of cancer at baseline, were assessed. Inbody (Biospace Co®) was used to measure PhA. All analyses were performed separately for each sex. According to the second tri-sectional quantile range of BMI and PhA, all patients were divided into relatively low and high groups. The survival rate was calculated using Kaplan-Meier analysis, and the difference between groups was compared using the Log-rank test. Cox regression analysis was used to analyze factors that could affect the prognosis of patients.
      Results  PhA in men (5.56±0.71)° was statistically different from that in women (4.69±0.91)°, P < 0.001. Multivariate analysis showed that PhA (HR=0.646, 95%CI: 0.486-0.860, P=0.003) was an independent prognostic factor in patients with SCLC. The median PFS of patients in the low and high PhA groups were 7.77 and 10.50 months, respectively. The Log-rank test showed a statistical difference between both groups (P < 0.05).
      Conclusions  PhA is a good predictor of prognosis in patients with SCLC. PhA differs between sexes. Further investigation should be conducted to explore the effective cutoff value of PhA for different diseases in East Asia.

     

    • HTML全文
    • 参考文献(26)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回